Navigation Links
New Insights into Antimalarial Drug Resistance

Researchers at Georgetown University Medical Center say they are moving closer to understanding why the most lethal form of human malaria has become resistant to drug treatment in the past three decades. They have been able to artificially construct, and then express in yeast, a protozoan gene that contributes to such resistance.

The gene they laboriously constructed over a two-year period is believed to be the largest synthetic one ever built, and it successfully produces large quantities of the encoded protein, whose function can now be easily studied.

The researchers say that with the addition of the recreated gene, PfMDR1 and its protein, they have all the biomolecular tools necessary to molecularly understand how the malarial parasite Plasmodium falciparum (P. falciparum), has become resistant to most of the drugs that could once destroy it. They have already described and expressed two other genes known to confer drug resistance.

Now that we have these genes expressed in a convenient yeast system, we can work to understand the molecular basis of anti-malarial drug resistance, providing insight into how future drugs might be designed to effectively kill the parasite, said Paul Roepe, PhD, a professor in the Department of Biochemistry and Cellular & Molecular Biology and the Department of Chemistry.

Any animal with red blood cells can develop malaria, which is caused by a single-cell protozoan parasite transmitted by the bite of the female Anopheles mosquito. There are about 160 different species of malaria parasites, according to Roepe. Five infect humans, but P. falciparum is responsible for about 1 million deaths out of 300 million acute cases of infection each year. Most of these deaths occur in young children living in sub-Saharan Africa.

Roepe and his collaborators at Georgetown University, in collaboration with investigators at the National Instit
'"/>




Page: 1 2 3 4

Related medicine news :

1. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
2. Reindeer Provide Valuable Insights Into Sleep Disorders
3. Insights Into Lead Pollution
4. Insights into Osteosarcoma in Cats and Dogs may Improve Palliative Care
5. New Insights into Chronic Inflammation and Atherosclerosis
6. Neural Basis of Anxiety: Newer Insights
7. Antihistamine Could also be used as a Potential Antimalarial Drug
8. Link between birth weight and Insulin Resistance
9. Easier Methods Required to Screen Insulin Resistance
10. Easier Methods Required to Screen Insulin Resistance
11. Insulin Resistance Linked To Difference In Gender
Post Your Comments:
(Date:7/8/2008)...following statement was issued,today by the law fi...otice is hereby given that a class action lawsuit ...the Middle District of Tennessee on behalf,of all ...q: HWAY ),("Healthways" or the "Company") from Oc...e (the "Class Period")., If you wish to discuss t...
(Date:7/8/2008)...elays in Oxygen Orders, Lack of,Trained Technician... -- The new Medicare,competitive bidding program f...nd chaos for beneficiaries, physicians, hospital d...viders across the country since it,was implemented... program has triggered widespread disruptions in s...
(Date:7/8/2008)...ociety of Hematology (ASH) is proud to announce th... Pathway Grant. The grant is given to training pro...plementation of novel hematology-related training ...sity, Donald Mahoney Jr., MD, of Baylor College of...Sinai School of Medicine, will each receive the gr...
(Date:7/8/2008)...os Innovation,s Proprietary,Device-Free Remote Mo... and Medical Costs, N...ovations, a pioneer,in assisting clients to achiev...ce improvement through a device-free remote monito...e Iowa Medicaid Congestive Heart Failure,Populatio...
Breaking Medicine News(10 mins):Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 4Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 5Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 3
...by Japanese government and produced by Unicef, the... Food and Agriculture// Organization, features Jac...untries and some colorful origami birds urging chi...In the advertisement shot in English at Sha Tin Ju...
...Britain and promoted by pop star Beyonce Knowles, ...ays.// All over the country, health shops are se...he shelves after pop star Beyonce Knowles said she... her latest film. The syrup, is said to be made ...
...desh to help malnourished children is yet to make ...led to aid the 5.7 million malnourished children o... age, Grassroots Features reported. Two-and-a-hal...riya tribal couple's daughter from Amolpath villag...
...iversity published his findings on a better substi...his month//. According to peer-reviewed research p...the kind of immune response doctors were looking f...ing, the vaccine was given to 100 volunteers at fo...
Other Medicine News:Health News:Scheme for Combating Malnourishment in MP Children Yet to Pick Up 2
(Date:7/7/2008)...- Light Sciences Oncology, Inc.,(LSO) today announ...enign,prostatic hyperplasia (BPH), or enlargement ...(Litx(TM)), an innovative light-activated drug,tre...2-patient, Phase I/II,dose-escalation study at fou...nt, Phase IIa study in Australia, expected to begi...
(Date:7/7/2008)...irstCall/ -- Biopure Corporation,(Nasdaq: BPUR ) ...he Food,and Drug Administration (FDA) on identifyi...ical trial of Hemopure(R) [hemoglobin glutamer -,2... study use of Hemopure,in patients suffering from ...usion with blood components. Currently, AML patien...
(Date:7/6/2008)...horization Application currently ...- Cell Therapeutics, Inc. (...lication of results from its,randomized phase III ...,CT-2103) with gemcitabine or vinorelbine for the ...with previously untreated non-small cell,lung canc...
(Date:7/3/2008)...sachusetts, July 3,/-, -...ny, Jerini AG for an equity purchase price of EUR...oduct, FIRAZYR(R), to its Human Genetic Therapies ...es expected to be around $350-400 million, based ...ent, - Expected to be accretive for Non GAAP earn...
Breaking Medicine Technology:Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 2Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 3Biopure Announces Meeting With FDA 2Biopure Announces Meeting With FDA 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 2Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 4Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 5Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 6Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 7Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 8Drug Resistant Staph Infections Reaching Epidemic Levels in Some Parts of U S 4151 1Drug Resistant Staph Infections Reaching Epidemic Levels in Some Parts of U S 4151 2Drug Resistant Staph Infections Reaching Epidemic Levels in Some Parts of U S 4151 3Drug Resistant Staph Infections Reaching Epidemic Levels in Some Parts of U S 4151 4Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 1Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 2Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 3Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 4Syngenta Licenses Chromatin Gene Stacking Technology 1373 1Syngenta Licenses Chromatin Gene Stacking Technology 1373 2Research approved for Hawaiian military training area 888 1Research approved for Hawaiian military training area 888 2
...nt Plans - , ,OTTAWA, Canada – March 7, 2007...al company specializing in developing,advanced pro...ften,called “good cholesterol,” today ... of its lead product, CRD5. CRD5 is,being develope...ase. , ,Results showed, to date, that CRD5 was saf...
... 12, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB...ectious disease and dermatology, today announced t...emonstrated virtually no biofilm,formation in a 21...treated with Ceragenins,were soaked daily in a pho...atheter. At day 21, the catheters were challenged ...
Other Medicine Technology:Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: